All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
What do phase II data show about the safety of imetelstat in R/R MF?
During the EHA2021 Virtual Congress, the MPN Hub spoke with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What do phase II data show about the safety of imetelstat in relapsed/refractory myelofibrosis (MF)?
What do phase II data show about the safety of imetelstat in R/R MF?
In this video, Mascarenhas discusses the results of a safety analysis of imetelstat based on two phase II trials conducted in MDS (IMerge study) and MF (IMbark study) settings.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox